Molecular characterization of leukemic cells is a continuously emerging field and has become fundamental for therapy stratification and prediction of event-free survival (EFS). Infant acute myeloid leukemia (AML) is in 460% cases characterized by a genomic rearrangement involving the mixed lineage leukemia (MLL) locus (11q23) and the expression of a fusion protein (450 fusion partners are described). Patients with primary diagnosis of MLL-positive leukemia are young (o2 years) and have generally an inferior outcome compared with MLL-negative patients. 1 We and others recently described a separate cohort of MLL-negative infant AML characterized by an early disease onset (o2 years) as well as t(7;12) HLXB9/TEL ( ¼ MNX1/ETV6) rearrangement and with concomitant high expression of HLXB9 (MNX1). Surprisingly, all patients relapsed having a 3-year EFS of 0%. 2, 3 The role of HLXB9, a transcription factor of the family of homeobox proteins is rarely studied in hematopoiesis and the data regarding its ability to cause malignant transformation of hematopoietic stem cells (HSCs) is not yet available. Interestingly, germline mutations of HLXB9 lead to annorectal malformations and Currarino syndrome in children, but hematopoietic abnormalities are not described. 4 The poor clinical outcome in this HLXB9/TEL-positive leukemia subset prompted us to comprehensively characterize the two entities of MLL-and HLXB9/TEL-positive AML regarding their cellular morphology, transcriptional profile and transformation process.
The MLL-positive cohort comprised six patients (t(9;11); MLL-AF9, verified by fluorescence in situ hybridization and polymerase chain reaction, French-American-British (FAB) subtype M5), who met the following criteria: diagnosis of AML, ageo2 years, blast content 460%, no trisomy 21. Immunologic analysis revealed AML with coexpression of T-cell-associated antigens CD4 (mean: 81.25%), CD7 (mean: 26%) ) altered genes in t(7;12) patients compared with t(11q23) patients representing a group of downregulated HOX genes and upregulated cell-cell interacting genes. (e) Relative expression of HLXB9, HOXA9, MEIS1 and C-MYB in t(7;12) and 11q23 patients. Quantitative real-time PCR was carried out in triplicates using TaqMan primer probe assays (Applied Biosystems, Darmstadt, Germany). Samples were normalized to b-ACTIN and DC t values were calculated. A significant difference was found for HLXB9 expression (Po0,05, Mann-Whitney U-test). t(7;12)-positive AML: n ¼ 5; t(11q23) AML/ALL: n ¼ 8, or CD56 (mean: 42.8%). In a cohort of 42 MLL-negative patients gathered in Germany and selected by the same clinical criteria, we detected a HLXB9/TEL transcript in six patients (incidence of 14%). All karyotypes were associated with trisomy 19 or an additional, not further characterized marker chromosome, a hallmark of this leukemia entity. The junction of the rearrangement fused HLXB9 exon 1 and TEL exon 3 (CAACT/GCTTG, in frame) in all positive patients analyzed by reverse transcriptase-PCR, subcloning and sequencing. A second out-of-frame variant fusing HLXB9 exon 1 and TEL exon 2 (mRNA fusion: CAACT/CAGGA, out of frame in TEL) was detected in a subset of patients (Figure 1a ). Clinically four patients had relapse, received allogeneic bone marrow transplantation and still remain in remission. One patient died after the fourth relapse and allogeneic transplantation. Clinical information of one patient is missing. Morphology was defined as FAB subtype M0 or M2 and the immunophenotype showed the expression of myeloid antigens CD13/CD33/CD15 and coexpression of T-cell-associated antigens CD7/CD4/CD56 (mean expression of CD7: 72%, CD4: 50%, CD56: 16%; Table 1 ). CD34 expression was significantly higher in HLXB9/ TEL compared with MLL-positive patients (71 vs 0.5%; P ¼ 0.014, Mann-Whitney U-test) (own data and von Bergh et al.
3 ). Similarly CD117 was highly expressed in HLXB9/TELpositive patient cells (mean 64 vs 34%; Table 1 ). The biphenotypic features of the HLXB9/TEL-positive blasts and the fact that early T-cell progenitors in the thymus retain myeloid potential directed us to study V(D)J recombination in the blast cells. 5 Neither in immunofluorescence nor by amplification of DH-JH, Db-Jb or T-cell receptor-d segments using multiplexmultifluorescent PCR and GeneScan analysis, we succeeded in detecting an immature T-cell receptor rearrangement in the analyzed patients (data not shown). This is arguing against the hypothesis that the HLXB9/TEL-positive blasts arise from T-cell precursors, which have already started V(D)J recombination in the thymus.
In view of the clinical and immunophenotypic similarities of the two leukemia entities, such as young age at diagnosis, coexpression of myeloid and T-cell antigens and bad clinical outcome, we aimed to characterize the molecular footprint representing the two leukemia entities. Gene expression profiles of MLL-positive acute lymphoblastic leukemia and AML are very well studied and a recent report described specific MLL-associated and upregulated genes, such as MEIS1 and HOX genes, in discrepancy to MLL-negative leukemia, using the Affymetrix platform (Affymetrix, Santa Clara, CA, USA). 6 The most frequent and differentially expressed HOX genes in human MLL-positive leukemia are HOXA5 and HOXA9. MLL fusion proteins can induce transcription from the HOXA9 and MEIS1 locus and probably promote transformation, extensively shown in murine transplantation models. 1 In contrast, almost nothing is known about the gene expression pattern of t(7;12)-positive leukemia.
Comparative gene expression profiling of leukemic blasts, collected from the indicated HLXB9/TEL and MLL patients, revealed significant downregulation of HOX genes such as  PBX3, HOXA9, HOXA6, HOXA5, HOXA10, HOXA3, HOXA4 , HOXA7, HOXA2 in HLXB9/TEL patients using the Affymetrix platform (Figures 1c and d) . Especially genes characteristic for the MLL-induced transformation process such as MEIS1, HOXA9 and C-MYB were downregulated in HLXB9/TEL-positive patients whereas HLXB9 was upregulated compared with MLL-positive and other, not further characterized entities of infant AMLs, as shown by quantitative RT-PCR (Figure 1e ; data not shown). This strongly suggests another transformation mechanism in HLXB9/TEL-positive hematopoietic precursors compared with MLL-positive cells.
Interestingly, we observed upregulation of genes, implicated in cell-cell interactions and cell adhesion such as EDIL3, CNTNAP5, ANGPT1, DSG2, ITGA9, ITGAV, KDR and SIGLEC6 in HLXB9/TEL-positive patients (Figures 1c and d) . Expression levels of ANGPT1 and KDR, the ligands of TIE2 and VEGFR, are of special interest because the related signaling pathways are important for the maintenance of quiescent HSCs and a physiologic HSC niche. 7 Consistently, the HLXB9/TEL gene expression profile revealed expression of early hematopoietic marker genes such as KITL and CD34, corresponding with the immunotypic findings. To further investigate the ability for malignant transformation of HLXB9/TEL or HLXB9 in comparison with MLL fusion proteins, we collected murine wild-type HSCs from 5-fluoruracil-treated mice and transduced the cells with a g-retroviral vector expressing MLL/ENL, HLXB9, HLXB9/TEL, HLXB9/TEL þ HLXB9 or an empty g-retroviral vector and subsequently plated the cells on methylcellulose. After three rounds of replating, MLL/ENL-transduced HSCs continued to form colonies, whereas cells overexpressing HLXB9 and HLXB9/TEL did not, indicating a high self-renewal capacity of MLL but not of HLXB9-or HLXB9/TEL-transduced cells (Figure 1f ). This result suggests that HLXB9 does not function by a block of HSC differentiation as it was previously described for MLL fusion proteins. Rather, the inability of In the past decade, several tumor-associated antigens have been reported to induce immune responses in acute myeloid leukemia (AML) patients. These antigens include human telomerase reverse transcriptase, proteinase 3, Wilms' tumor 1 protein, the preferentially expressed antigen in melanoma protein, survivin and the receptor for hyaluronic acid-mediated motility (RHAMM). [1] [2] [3] The M-phase phosphoprotein 11 (MPP11) gene, a member of the MPP family, encodes a 66 kDa protein and is located on the chromosome 7q22-q31.1.
2-4 It has been documented that MPP11 is capable of forming a heterodimeric complex that associates with ribosomes, acting as a molecular chaperone for nascent polypeptide chains as they exit the ribosome. 5, 6 By using serological screening of an expression library, Greiner et al. described MPP11 as a cancer testis antigen, which is highly upregulated in malignant myeloblasts in patients with AML and chronic myeloid leukemia, but is absent in normal differentiated tissues except for testis. In a small sample size, the authors were capable of showing significant titers of anti-MPP11 antibodies in some AML and chronic myeloid leukemia patients. 2, 3 In the current study, we identified T-cell epitopes capable of inducing specific cytotoxic T cell line
